Concerns about the approval of #lecanemab for Alzheimer’s disease
"...We are concerned about the approval of this #drug with uncertain net benefit that might foster false hope and expectations among people with #Alzheimer’s disease and their #carers and which might further overburden already overstretched #healthcare systems in Europe..."